Float Short %

2.83

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

0.05

EPS Last/This Y

0.19

EPS This/Next Y

0.55

Price

1.4

Target Price

5.75

Analyst Recom

Performance Q

-12.5

Relative Volume

0.69

Beta

-0.3

Ticker: ATNM

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	ATNM	1.3299	0.01	0.00	3706
2025-11-11	ATNM	1.29	0.01	0.00	3805
2025-11-12	ATNM	1.315	0.01	0.00	3805
2025-11-13	ATNM	1.24	0.01	0.00	3826
2025-11-14	ATNM	1.3	0.01	0.00	3866
2025-11-17	ATNM	1.465	0.01	0.00	3901
2025-11-18	ATNM	1.41	0.01	0.00	4361
2025-11-19	ATNM	1.33	0.01	0.10	4572
2025-11-20	ATNM	1.29	0.01	0.00	4641
2025-11-21	ATNM	1.32	0.01	0.00	4779
2025-11-24	ATNM	1.39	0.01	0.00	2607
2025-11-25	ATNM	1.38	0.01	0.00	2747
2025-11-26	ATNM	1.46	0.01	0.00	2775
2025-12-01	ATNM	1.37	0.01	0.00	2968
2025-12-02	ATNM	1.37	0.01	0.00	3174
2025-12-03	ATNM	1.46	0.01	0.00	3187
2025-12-04	ATNM	1.45	0.01	0.00	3187
2025-12-05	ATNM	1.42	0.01	0.00	3197
2025-12-08	ATNM	1.415	0.01	0.00	3208
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	ATNM	1.33	12.6	-	-1.24
2025-11-11	ATNM	1.31	12.6	-	-1.24
2025-11-12	ATNM	1.32	12.6	-	-1.24
2025-11-13	ATNM	1.24	12.6	-	-1.24
2025-11-14	ATNM	1.29	12.6	-	-1.24
2025-11-17	ATNM	1.46	12.6	-	-1.24
2025-11-18	ATNM	1.41	12.6	-	-1.24
2025-11-19	ATNM	1.36	12.6	-	-1.24
2025-11-20	ATNM	1.29	12.6	-	-1.24
2025-11-21	ATNM	1.32	11.9	-	-1.08
2025-11-24	ATNM	1.39	11.9	-	-1.08
2025-11-25	ATNM	1.40	11.9	-	-1.08
2025-11-26	ATNM	1.46	11.9	-	-1.08
2025-12-01	ATNM	1.38	11.9	-	-1.08
2025-12-02	ATNM	1.38	11.9	-	-1.08
2025-12-03	ATNM	1.45	11.9	-	-1.08
2025-12-04	ATNM	1.44	11.9	-	-1.08
2025-12-05	ATNM	1.43	11.9	-	-1.08
2025-12-08	ATNM	1.40	11.9	-	-1.08
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	ATNM	0.00	-8.72	2.72
2025-11-11	ATNM	0.00	-8.72	2.72
2025-11-12	ATNM	0.00	-8.72	2.82
2025-11-13	ATNM	0.00	-8.72	2.82
2025-11-14	ATNM	0.00	-8.72	2.82
2025-11-17	ATNM	0.00	-0.05	2.82
2025-11-18	ATNM	0.00	-0.05	2.82
2025-11-19	ATNM	0.00	-0.05	2.82
2025-11-20	ATNM	0.00	-0.05	2.82
2025-11-21	ATNM	0.00	-0.05	2.82
2025-11-24	ATNM	0.00	-1.13	2.82
2025-11-25	ATNM	0.00	-1.13	2.82
2025-11-26	ATNM	0.00	-1.13	2.83
2025-12-01	ATNM	0.00	-1.05	2.83
2025-12-02	ATNM	0.00	-1.05	2.83
2025-12-03	ATNM	0.00	-1.05	2.83
2025-12-04	ATNM	0.00	-1.05	2.83
2025-12-05	ATNM	0.00	-1.05	2.83
2025-12-08	ATNM	0.00	0	2.83
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.11

Insider Transactions

Institutional Transactions

Beta

-0.3

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

90.7

Max Drawdown 5-Year %

-92.6

Target Price

5.75

P/E

Forward P/E

PEG

P/S

485.27

P/B

3.17

P/Free Cash Flow

EPS

-1.11

Average EPS Est. Cur. Y

-1.08

EPS Next Y. (Est.)

-0.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-38443.33

Relative Volume

0.69

Return on Equity vs Sector %

-277.9

Return on Equity vs Industry %

-263

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.25

EBIT Estimation

Actinium Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 25

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

stock quote shares ATNM – Actinium Pharmaceuticals Inc Stock Price stock today

news today ATNM – Actinium Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ATNM – Actinium Pharmaceuticals Inc yahoo finance google finance

stock history ATNM – Actinium Pharmaceuticals Inc invest stock market

stock prices ATNM premarket after hours

ticker ATNM fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ATNM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y